DDInter1837 DDInter1676
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Toremifene {u} (Compound) resembles {v} (Compound) Doxylamine
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
Toremifene {u} (Compound) upregulates {v} (Gene) SQSTM1
Toremifene {u} (Compound) downregulates {v} (Gene) PMM2
Toremifene {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Toremifene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metolazone
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Toremifene (Compound) resembles Doxylamine (Compound)
Toremifene (Compound) treats breast cancer (Disease)
Toremifene (Compound) binds ABCB1 (Gene)
Toremifene (Compound) upregulates SQSTM1 (Gene)
Toremifene (Compound) downregulates PMM2 (Gene)
Toremifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Toremifene may lead to a major life threatening interaction when taken with Pazopanib